COMBIGAN® (brimonidine tartrate/timolol maleate ophthalmic solution) 0.2%/0.5% is approved for reducing elevated intraocular pressure (IOP) in patients with glaucoma who require additional or adjunctive IOP-lowering therapy. COMBIGAN® lowers IOP slightly less than both brimonidine tartrate taken three times a day and timolol maleate taken two times a day.
IMPORTANT SAFETY INFORMATION
Contraindications: COMBIGAN® ophthalmic solution should not be used by patients who have, or ever had bronchial asthma, chronic bronchitis, emphysema, slow heartbeat, impaired conduction of the heart, heart failure, or impaired pumping of the heart, or by patients with hypersensitivity to any ingredient of this product.
Warnings and Precautions: Severe respiratory reactions including death due to difficulty breathing have been reported in patients with asthma. Stimulation of the nervous system may be essential in individuals with diminished heart pumping ability. In patients without a history of cardiac failure, continued use of beta-blocking agents over a period of time can, in some cases, lead to cardiac failure. Patients with mild or moderate chronic bronchitis, emphysema, or asthma should not take COMBIGAN® ophthalmic solution. COMBIGAN® may worsen symptoms associated with poor circulation. COMBIGAN® patients who have allergies may experience stronger allergy symptoms than they would without COMBIGAN® ophthalmic solution. Patients may experience muscle weakness or fatigue. COMBIGAN® may mask hypoglycemic symptoms in patients with diabetes mellitus. Certain clinical signs of hyperthyroidism may be masked, such as rapid heartbeat. Patients with overactive thyroid who withdraw too abruptly from COMBIGAN® may experience severe hyperthyroid symptoms.
Adverse reactions: The most common adverse reactions occurring in approximately 5% to 15% of patients included allergic inflammation of the eye, abnormally large lymph follicles in the mucous membrane lining the inner surface of the eyelid and the exposed surface of the eyeball (also called the conjunctiva), eye redness, severe itching of the eye, and burning and stinging
of the eyes.
FULL PRODUCT INFORMATION